SS Innovations International, Inc. (NASDAQ: SSII) has reported significant growth in the adoption and utilization of its SSi Mantra surgical robotic system, according to a recent investor update. As of September 8, 2026, the company has facilitated 14,103 cumulative procedures, a 79% increase from 7,885 at the end of 2025. The installed base of SSi Mantra systems has also risen 42%, reaching 238 units across 12 countries, up from 168 systems previously.
The expansion highlights the company's progress in making robotic surgery more accessible. Approximately 1,500 physicians have been trained on the platform, which now supports more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the first installation of an SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines.
Additionally, SS Innovations reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, including a landmark telesurgery spanning over 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, demonstrating the system's efficiency and reliability.
Looking forward, the company anticipates that the U.S. Food and Drug Administration will complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. SS Innovations also believes it can obtain European Union CE marking certification by year-end 2026. These regulatory milestones could open major new markets for the company.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the proprietary SSi Mantra surgical robotic system and the comprehensive suite of SSi Mudra surgical instruments, which support a variety of procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
For investors, the update underscores SS Innovations' rapid commercialization and potential to disrupt the surgical robotics market, which has traditionally been dominated by expensive systems. The growth in procedures and installations suggests increasing trust among surgeons and hospitals, particularly in emerging markets. If the company secures FDA clearance and CE marking, it could compete more directly with established players in the U.S. and Europe, potentially driving further adoption and revenue growth.
To view the full report, visit https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
